Omnicell director granted 4,845 restricted shares

Seim Robin Gene reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Seim Robin Gene reported acquisition or exercise transactions in this Form 4 filing.

Omnicell director Robin Gene Seim received a grant of 4,845 shares of common stock as equity compensation. The shares are restricted and were awarded under Omnicell's equity incentive plan for service on the Board of Directors.

These restricted shares will vest in full on the one-year anniversary of the grant date. Following this award, Seim directly holds a total of 52,198 shares of Omnicell common stock.

Insider Trade Summary

Grant/Award: 4,845 shares

Grant/Award 1 txn

Insider Seim Robin Gene

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,845	$0.00	$0.00

Holdings After Transaction: Common Stock — 52,198 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date.

Key Figures

Restricted shares granted: 4,845 shares Grant price: $0.0000 per share Total shares after grant: 52,198 shares +2 more

5 metrics

Restricted shares granted 4,845 shares Grant of common stock as board compensation

Grant price $0.0000 per share Stated transaction price for restricted stock award

Total shares after grant 52,198 shares Direct holdings following the award

Vesting schedule One-year cliff vesting Shares vest in full on one-year anniversary of grant date

Security type Common Stock Non-derivative equity award

Key Terms

restricted shares, equity incentive plan, Board of Directors Compensation Plan, vest in full, +1 more

5 terms

restricted shares financial

"Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

equity incentive plan financial

"Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Board of Directors Compensation Plan financial

"services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan"

vest in full financial

"Shares shall vest in full on the one-year anniversary of the grant date"

grant date financial

"Shares shall vest in full on the one-year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Omnicell (OMCL) director Robin Gene Seim report in this Form 4?

Robin Gene Seim reported receiving a grant of 4,845 restricted shares of Omnicell common stock. The award was made as compensation for service on Omnicell’s Board of Directors under the company’s equity incentive and board compensation plans.

How many Omnicell (OMCL) shares does Robin Gene Seim hold after this grant?

After the grant, Robin Gene Seim directly holds 52,198 shares of Omnicell common stock. This total includes the newly granted 4,845 restricted shares, which are subject to vesting conditions tied to continued board service for one year.

What are the terms of the 4,845 restricted Omnicell (OMCL) shares granted to Robin Gene Seim?

The 4,845 Omnicell shares are restricted stock granted at no cash cost under the company’s equity incentive plan. According to the disclosure, the shares will vest in full on the one-year anniversary of the grant date, contingent on continued board service.

Why did Omnicell (OMCL) grant restricted shares to director Robin Gene Seim?

The restricted shares were granted as consideration for Robin Gene Seim’s services as a Board Member. The award was made pursuant to Omnicell’s equity incentive plan and its Board of Directors Compensation Plan, aligning director compensation partly with company equity.

Is this Omnicell (OMCL) Form 4 transaction a market purchase or sale of shares?

No, this Form 4 reflects a grant or award acquisition, not a market trade. The 4,845 shares were granted as restricted stock compensation at a stated price of $0.0000 per share, rather than bought or sold on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seim Robin Gene

(Last) (First) (Middle)

OMNICELL, INC.

4220 NORTH FREEWAY

(Street)

FORT WORTH TEXAS 76137

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OMNICELL, INC. [ OMCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		4,845(1)	A	$0	52,198	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date.

	/s/ Eric Lehmann, Attorney-in-Fact for Robin G. Seim	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)